Abstract

Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer. Human health is at risk due to the fact that only 10% survive for five years. HCC is treated with surgery, radiotherapy, and chemotherapy as the main methods. However, traditional treatment methods have certain side effects, surgical treatment requires postoperative intensive care, radiotherapy and chemotherapy can damage normal liver tissue, lead to fatigue and nausea and other symptoms, affecting the quality of life of patients. The treatment of hepatocellular carcinoma has been greatly benefited from the development of Chimeric antigen receptor T (CAR-T) cell therapy, which is considered one of the most innovative immunotherapies. Compared to traditional therapies and other immunotherapies, it is highly targeted and can survive and kill tumor cells for a long time. CAR-T cell therapy has become the focus of modern basic medical research and clinical trials. This article reviews the advantages, disadvantages, prospects and challenges of CAR-T cell therapy for liver HCC.